Skip to Main Content

WASHINGTON — Forgive us if you read our stories on this topic from 2017 and 2018, but here it comes again: Another year has passed since the Drug Enforcement Administration said it was open to approving more suppliers of marijuana for scientific research, and another year has passed without an application being approved.

The lag has increasingly frustrated scientists, advocates, and members of Congress from both parties who argue that expanding research into marijuana could lead to new medicines and help identify what health risks use presents.


It’s also created an odd juxtaposition, as the availability of and interest in marijuana surges in other ways. A growing number of states have legalized marijuana for medical and, in some cases, recreational purposes. Consumer products made from cannabidiol — a component of marijuana that can also be derived from hemp — are flooding wellness shops, cafes, and beauty stores in ever increasing varieties. And last year, the Food and Drug Administration approved the country’s first prescription drug derived from marijuana, a cannabidiol product called Epidiolex that treats types of epilepsy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • The DEA is funded through the ONDCP snd operates by it’s laws and regulations.
    According to Title VII Office of National Drug Control Policy Reauthorization Act of 1998: H11225:

    Responsibilities. –The Director– […]

    (12) shall ensure that no Federal funds appropriated to the Office of National Drug Control Policy shall be expended for any study or contract relating to the legalization (for a medical use or any other use) of a substance listed in schedule I of section 202 of the Controlled Substances Act (21 U.S.C. 812) and take such actions as necessary to oppose any attempt to legalize the use of a substance (in any form) that–

    A. is listed in schedule I of section 202 of the Controlled Substances Act (21 U.S.C. 812); and
    C. has not been approved for use for medical purposes by the Food and Drug Administration;
    The above law requires them to not help remove cannabis from Schedule 1 and Joe Biden was on the panel that wrote it.
    Agents can lie under oath,,ruled ok by an appeals court because they are doing their job tryng to keep cannabis Schedule 1.

  • If reporter Joseph had a bit more technical interest, he would probably have told readers that the federal marijuana from Mississippi is your grandfather’s marijuana, with tetrahydrocannibiol (THC) content around 3 percent. State surveys where marijuana has been legalized show THC content around 15 percent, owing to optimized greenhouse practices. The much higher THC content is more likely to cause acute problems and may be more likely to induce long-term decline in mental performance. Controlled research in the United States cannot currently find out.

  • The DEA should be held accountable for procrastinating on progress that would support R & D for medical purposes. They are archaic in their stance on the cannabis plant (still Schedule 1 ??? ridiculous !!!), and utterly uncooperative. And in their stubborn old ways they are blocking crucial progress for research that could lead to very valuable and effective medicine. This is unacceptable, and I hope the lawsuit on the DEA’s inactivity and broken time-lines will be effective.

Comments are closed.